Nateglinide Side Effects

For the Consumer

Applies to nateglinide: oral tablet

As well as its needed effects, nateglinide may cause unwanted side effects that require medical attention.

Major Side Effects

If any of the following side effects occur while taking nateglinide, check with your doctor immediately:

• Convulsions (seizures)
• unconsciousness

Severity: Moderate

If any of the following side effects occur while taking nateglinide, check with your doctor or nurse as soon as possible:

• Low blood sugar, including anxious feeling, behavior change similar to being drunk, blurred vision, cold sweats, confusion, cool pale skin, difficulty in thinking, drowsiness, excessive hunger, fast heartbeat, headache, nausea, nervousness, nightmares, restless sleep, shakiness, slurred speech, or unusual tiredness or weakness

• Hives or welts
• itching
• redness of skin
• skin rash

Minor Side Effects

Some nateglinide side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

• Cough
• runny or stuffy nose
• sore throat

• Abdominal or stomach pain
• back pain
• chills
• dizziness
• pain in joints or muscles
• sneezing
• swelling in joints

For Healthcare Professionals

Applies to nateglinide: oral tablet

General

The most frequently reported adverse events included upper respiratory tract infections and symptoms of hypoglycemia.^[Ref]

Metabolic

Common (1% to 10%): Hypoglycemia
Frequency not reported: Increases in mean uric acid level^[Ref]

Hypoglycemia has been reported and has generally been mild and corrected by intake of carbohydrates. In comparative clinical trials, hypoglycemia was reported in 10.4%, 14.5%, 6.9%, 19.8%, and 4.1% in patients receiving nateglinide alone, nateglinide plus metformin, metformin alone, glyburide alone, and placebo, respectively.

Mean uric acid levels were increased in patient receiving this drug as monotherapy. The difference from placebo in treated patients was 0.29 mg/dL, 0.45 mg/dL, 0.28 mg/dL, and 0.19 mg/dL in patients receiving nateglinide alone, nateglinide plus metformin, metformin alone, glyburide alone, respectively. The clinical significance of these findings is unknown.^[Ref]

Respiratory

Common (1% to 10%): Upper respiratory tract infection, bronchitis, coughing^[Ref]

Hypersensitivity

Postmarketing reports: Hypersensitivity reactions such as rash, itching, and urticaria^[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea, abdominal pain, dyspepsia, nausea
Uncommon (0.1% to 1%): Vomiting^[Ref]

Gastrointestinal symptoms, especially diarrhea and nausea, were no more common in patients using this drug in combination with metformin than in patients receiving metformin alone.^[Ref]

Hepatic

Postmarketing reports: Elevated liver enzymes, jaundice, cholestatic hepatitis^[Ref]

Nervous system

Common (1% to 10%): Dizziness^[Ref]

Musculoskeletal

Common (1% to 10%): Back pain, arthropathy^[Ref]

Cardiovascular

Peripheral edema was no more common in patients using this drug in combination with rosiglitazone than in patients receiving rosiglitazone alone.^[Ref]

Frequency not reported: Peripheral edema^[Ref]

Dermatologic

Postmarketing reports: Erythema multiforme^[Ref]

Immunologic

Common (1% to 10%): Flu symptoms^[Ref]

Other

Common (1% to 10%): Accidental trauma^[Ref]

It is possible that some side effects of nateglinide may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.